In the past week, CLRB stock has gone up by 1.27%, with a monthly gain of 1.64% and a quarterly plunge of -86.82%. The volatility ratio for the week is 9.87%, and the volatility levels for the last 30 days are 9.15% for Cellectar Biosciences Inc The simple moving average for the past 20 days is 5.78% for CLRB’s stock, with a -85.29% simple moving average for the past 200 days.
Is It Worth Investing in Cellectar Biosciences Inc (NASDAQ: CLRB) Right Now?
The 36-month beta value for CLRB is at 0.99. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CLRB is 44.71M, and currently, shorts hold a 5.27% of that float. The average trading volume for CLRB on February 13, 2025 was 2.77M shares.
CLRB) stock’s latest price update
The stock price of Cellectar Biosciences Inc (NASDAQ: CLRB) has plunged by -2.75 when compared to previous closing price of 0.29, but the company has seen a 1.27% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-02-05 that FLORHAM PARK, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually. Details are as follows:
Analysts’ Opinion of CLRB
Many brokerage firms have already submitted their reports for CLRB stocks, with Ladenburg Thalmann repeating the rating for CLRB by listing it as a “Buy.” The predicted price for CLRB in the upcoming period, according to Ladenburg Thalmann is $13 based on the research report published on December 05, 2024 of the previous year 2024.
ROTH Capital gave a rating of “Buy” to CLRB, setting the target price at $10 in the report published on January 21st of the previous year.
CLRB Trading at -35.55% from the 50-Day Moving Average
After a stumble in the market that brought CLRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.72% of loss for the given period.
Volatility was left at 9.15%, however, over the last 30 days, the volatility rate increased by 9.87%, as shares surge +8.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -82.47% lower at present.
During the last 5 trading sessions, CLRB fell by -2.17%, which changed the moving average for the period of 200-days by -91.09% in comparison to the 20-day moving average, which settled at $0.2638. In addition, Cellectar Biosciences Inc saw -6.52% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CLRB
Current profitability levels for the company are sitting at:
- -156.13 for the present operating margin
- 0.32 for the gross margin
The net margin for Cellectar Biosciences Inc stands at -135.05. The total capital return value is set at -3.04. Equity return is now at value -474.63, with -170.31 for asset returns.
Based on Cellectar Biosciences Inc (CLRB), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -90.23. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -415.86.
Currently, EBITDA for the company is -38.77 million with net debt to EBITDA at 0.66. When we switch over and look at the enterprise to sales, we see a ratio of -63.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.77.
Conclusion
In conclusion, Cellectar Biosciences Inc (CLRB) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
